Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Who’s Going to SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

242 organizations at SITC 2026, a ~6,000-person meeting of cancer immunotherapy researchers and oncologists, evenly split between academia and biopharma. As of Sep 29, 2026.

Showing 1–6 of 242 organizations

Organization	SITC 2026 Attendance
U.S. Food and Drug Administration Silver Spring, MD
fda.gov Government & non-profit U.S. federal agency that regulates drugs, biologics and medical devices, including cancer immunotherapies.	Session Wed Nov 4 2:10pm–2:55pm Panel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics Encanto AB Regulatory Session Wed Nov 4 3:10pm–3:55pm Panel Discussion 2: Biomarker Discovery and Digital AI Encanto AB Biomarkers · AI & data Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Talk Fri Nov 6 2:45pm–3:00pm Part of Session 106b: Human Ex Vivo Models for Immunotherapy Testing: From Tumor Explants to Tumor-on-Chip From Conventional to New Approach Methodologies: Regulatory Considerations for Immuno-Oncology Safety Assessment 301A Regulatory · Models & tech
Dana-Farber Cancer Institute Boston, MA
dana-farber.org Cancer centres & hospitals Harvard-affiliated cancer treatment and research center in Boston.	Workshop Thu Nov 5 5:00pm–9:00pm Launching Biotech Startups: Funding, Pitching, Partnerships 5:00pm–5:45pmWelcome Reception 5:55pm–6:55pmHigh-Impact Talks from Pharma Leaders 6:55pm–7:15pmPanel 7:00pm–7:50pmFinancing and Partnership Panel 8:00pm–9:00pmClosing Networking Reception Plenary Fri Nov 6 8:40am–9:10am Part of Session 102: Richard V. Smalley Memorial Award and Lectureship Getting Off the Rollercoaster: Personalized Cancer Vaccines Come of Age Halls BC Vaccines Plenary Fri Nov 6 11:10am–11:30am Part of Session 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future The Cancer Dark Proteome: A Rich Source of Tumor-Selective Cryptic Antigens Halls BC Vaccines Session Fri Nov 6 9:40am–11:30am Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future Halls BC Vaccines 9:44am–10:04amDiscovery and Development of a Pancreatic Cancer RNA VaccineMemorial Sloan Kettering Cancer Center 10:04am–10:24amUpdates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted Kras VaccineScripps Research 10:24am–10:37amAbstract presentation — title not yet released 10:37am–10:57amLearning from Checkpoint Blockade: Prioritizing Neoantigens and Shared Tumor Antigens for Cancer VaccinesUniversity of Toulouse 10:57am–11:10amAbstract presentation — title not yet released 11:10am–11:30amThe Cancer Dark Proteome: A Rich Source of Tumor-Selective Cryptic AntigensDana-Farber Cancer Institute Talk Fri Nov 6 2:10pm–2:30pm Part of Session 106a: Combination Therapies Involving Cell Therapy CAR-Enhancers: Programmable Boosters for Durable Cell Therapy Halls BC Cell therapy Talk Fri Nov 6 2:30pm–2:45pm Part of Session 106b: Human Ex Vivo Models for Immunotherapy Testing: From Tumor Explants to Tumor-on-Chip Dynamic Immune Profiling Using Human Ex Vivo Tumor Models 301A Models & tech Session Sat Nov 7 5:20pm–6:40pm Oral Abstract Session 4 301D 5:20pm–6:35pm5 abstract presentations — titles not yet released
Massachusetts General Hospital Boston, MA
massgeneral.org Cancer centres & hospitals Harvard teaching hospital in Boston and home of the Mass General Cancer Center.	Session Thu Nov 5 12:00pm–1:30pm Collaborating with Industry Encanto AB Session Fri Nov 6 1:45pm–3:25pm Mechanisms of irAEs Hall A Clinical 1:50pm–2:10pmDiet and Microbiome Drivers of Immune Related Adverse EventsUniversity of Pittsburgh 2:10pm–2:30pmUnlocking the Specificity of the Autoimmune Response in iRAE’sUCSF 2:30pm–2:50pmClinical Trials for irAEs: Where Do We Go Next?Vanderbilt University Medical Center 2:55pm–3:25pm2 abstract presentations — titles not yet released Talk Sat Nov 7 4:15pm–4:25pm Part of Session 206c: Microbiome and Metabolism Gut Microbiota Metabolite Control of Antitumor CD8 T Cell Trafficking 301A Tumor biology Session Sat Nov 7 3:30pm–4:50pm IO in Low Mutation Burden Cancers Hall A Tumor biology 3:35pm–3:55pmTargeted Therapy + ImmunotherapyJohns Hopkins University 3:55pm–4:15pmFrom the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint TherapyMD Anderson Cancer Center 4:15pm–4:35pmBeyond the Canonical Proteome: Identifying Immunogenic Targets in Ovarian TumorsMayo Clinic 4:35pm–4:50pmAbstract presentation — title not yet released Session Sat Nov 7 3:30pm–4:50pm Microbiome and Metabolism 301A Tumor biology 3:30pm–3:45pmCorrecting the Gut Microbiome Dysbiosis in OncologyCentre hospitalier de l'Université de Montréal (CHUM) 3:45pm–4:00pmToward Metabotherapy for CancerStanford University 4:00pm–4:15pmIntratumoral Bacterial Elements in Brain TumorsMoffitt Cancer Center 4:15pm–4:25pmGut Microbiota Metabolite Control of Antitumor CD8 T Cell TraffickingMassachusetts General Hospital 4:25pm–4:35pmGut Microbiome Function Shapes the Efficacy of Tumor Infiltrating Lymphocyte (TIL) Therapy in MelanomaUniversity of Pittsburgh Talk Sat Nov 7 5:40pm–5:55pm Part of Session 207d: Cellular Therapies Learnings From a CAR-T Driver Into Solid Tumor Halls BC Cell therapy Talk Sun Nov 8 10:45am–11:00am Part of Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender? Biology of anti-VEGF treatment Hall A New agents · Tumor biology
National Cancer Institute Bethesda, MD
cancer.gov Government & non-profit US federal agency for cancer research and training, part of the National Institutes of Health.	Session Thu Nov 5 12:00pm–1:30pm Careers Outside Academia and Industry – Careers in Policy, Advocacy and Non-Profit Organizations Encanto AB Talk Thu Nov 5 3:35pm–3:50pm Part of Session I – Grant Writing Essentials Considerations for Using AI Encanto AB Talk Thu Nov 5 2:35pm–2:45pm Part of Session I – Grant Writing Essentials Overview of NIH Grants Encanto AB Session Fri Nov 6 8:00am–8:05am Presidential Welcome Halls BC Session Fri Nov 6 3:55pm–5:30pm Oral Abstract Session 2 301D 3:55pm–5:25pm6 abstract presentations — titles not yet released Talk Sat Nov 7 6:02pm–6:20pm Part of Session 207b: AI-driven Protein Design to Enhance Cancer Immunotherapy T cell phenotype and protein structure-informed discovery of TCRs for cell therapy 301BC Cell therapy · AI & data Session Sun Nov 8 8:15am–9:40am Presidential Session Hall A 8:20am–9:20am4 abstract presentations — titles not yet released 9:20am–9:30amExpert DisucussantUniversity of Pittsburgh
MD Anderson Cancer Center Houston, TX
mdanderson.org Cancer centres & hospitals University of Texas comprehensive cancer center in Houston focused on cancer patient care, research and education.	Session Thu Nov 5 12:00pm–1:30pm Career Paths for Physician Scientists Encanto AB Workshop Thu Nov 5 7:00pm–8:00pm Early Career Scientist Speed Mentoring 7:00pm–8:00pmSpeed Mentoring - Group Mentoring 7:00pm–7:30pmSpeed Mentoring - One-on-One 7:30pm–8:00pmSpeed Mentoring - One-on-One 2 Talk Sat Nov 7 10:00am–10:20am Part of Session 202: Spatial Biology Spatial Biomarkers of Immunotherapy Response Halls BC Biomarkers · Models & tech Talk Sat Nov 7 3:55pm–4:15pm Part of Session 206b: IO in Low Mutation Burden Cancers From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy Hall A Tumor biology Session Sat Nov 7 3:30pm–4:50pm Oral Abstract Session 3 301D 3:30pm–4:45pm5 abstract presentations — titles not yet released Talk Sun Nov 8 11:30am–11:45am Part of Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender? Biology and Clinical Results of Anti-VEGF+PD1 Bispecfics Hall A New agents
University of Pittsburgh Pittsburgh, PA
pitt.edu Universities & research institutes Public research university in Pittsburgh, Pennsylvania.	Session Thu Nov 5 12:00pm–1:30pm Navigating Academia as Junior Faculty (as MD or PhD) Encanto AB Talk Thu Nov 5 3:15pm–3:25pm Part of Session I – Grant Writing Essentials Funding Your Research Through Industry Collaboration Encanto AB Workshop Thu Nov 5 2:30pm–5:05pm Grant Writing Workshop 2:30pm–4:30pmSession I – Grant Writing Essentials 4:05pm–4:30pmThe Importance of the Patient Advocate Perspective in Research and How to Effectively Connect with Advocates 4:30pm–5:00pmSession II – Breakout Sessions 5:00pm–5:05pmClosing Talk Thu Nov 5 4:30pm–5:00pm Part of Session II – Breakout Sessions Breakout Table: Interfacing with Industry (Biotech Grants) Encanto AB Talk Thu Nov 5 4:30pm–5:00pm Part of Session II – Breakout Sessions Breakout Table: Low-preliminary Data Grants (DP5, R21, High Risk/High Reward Grants) Encanto AB Talk Fri Nov 6 1:50pm–2:10pm Part of Session 106d: Mechanisms of irAEs Diet and Microbiome Drivers of Immune Related Adverse Events Hall A Clinical · Tumor biology Session Sat Nov 7 9:35am–11:15am Spatial Biology Halls BC Models & tech 9:40am–10:00amHigh-plex Imaging and Spatial TranscriptomicsUniversity of Queensland 10:00am–10:20amSpatial Biomarkers of Immunotherapy ResponseMD Anderson Cancer Center 10:20am–10:40amComputational Spatial Biology and AI-assisted InterpretationProvidence Genomics 10:40am–11:10am2 abstract presentations — titles not yet released Session Sat Nov 7 11:15am–12:15pm Hot Topic Symposium: External Factors Contributing to Immunotherapy Response Halls BC Tumor biology 11:15am–11:30amPostprandial Metabolism and its Potential to Enhance Immunotherapy ResponsesUniversity of Pittsburgh 11:30am–11:45amThe Role of the Intestinal Microbiome in Cancer ImmunotherapyCity of Hope 11:45am–12:05pmDebate: Pros and Cons on Time of Day and Checkpoint InhibitorsEmory University School of Medicine, Fred Hutchinson Cancer Center Talk Sat Nov 7 11:15am–11:30am Part of Session 203: Hot Topic Symposium: External Factors Contributing to Immunotherapy Response Postprandial Metabolism and its Potential to Enhance Immunotherapy Responses Halls BC Tumor biology Talk Sat Nov 7 4:25pm–4:35pm Part of Session 206c: Microbiome and Metabolism Gut Microbiome Function Shapes the Efficacy of Tumor Infiltrating Lymphocyte (TIL) Therapy in Melanoma 301A Tumor biology · Cell therapy Session Sat Nov 7 3:30pm–4:50pm Microbiome and Metabolism 301A Tumor biology 3:30pm–3:45pmCorrecting the Gut Microbiome Dysbiosis in OncologyCentre hospitalier de l'Université de Montréal (CHUM) 3:45pm–4:00pmToward Metabotherapy for CancerStanford University 4:00pm–4:15pmIntratumoral Bacterial Elements in Brain TumorsMoffitt Cancer Center 4:15pm–4:25pmGut Microbiota Metabolite Control of Antitumor CD8 T Cell TraffickingMassachusetts General Hospital 4:25pm–4:35pmGut Microbiome Function Shapes the Efficacy of Tumor Infiltrating Lymphocyte (TIL) Therapy in MelanomaUniversity of Pittsburgh Plenary Sun Nov 8 9:20am–9:30am Part of Session 301: Presidential Session Expert Disucussant Hall A

Instantly find 20 buyers from companies at SITC 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

The SITC Annual Meeting is the yearly meeting of the Society for Immunotherapy of Cancer, the professional society for cancer immunotherapy. SITC 2026 — its 41st meeting and pre-conference programs — runs November 4–8, 2026 at the Phoenix Convention Center, bringing together academic and clinical immunotherapy researchers, oncologists, drug developers and the companies that supply them.

What is in this guide?

Every organization we can place at SITC 2026: 188 invited speakers, session chairs, moderators, panelists, lunch-table experts and pre-conference program organizers from the public schedule (106 invited talks across 91 sessions and programs), rolled up to their cancer centres, universities and companies, plus the 132 exhibitors on the floor plan with their booth numbers and the companies hosting sponsored symposia and tech talks — 242 organizations in one list. People appear as credentials, never by name.

Where do the named attendees come from?

From their own public posts. 5 people said on LinkedIn or Bluesky that they will be at SITC 2026, or were named in their organization’s post about it, across 4 posts. Each shows as a short quote from the post, with every person’s name removed, linked to the post itself. Posts that only promote a company, or that never say who will attend, are left out, and so is anyone already on the program.

How are organizations typed?

By the role an organization plays in cancer immunotherapy: universities and research institutes, cancer centres and hospitals, and government and non-profit bodies; pharma and biotech drug developers; then the suppliers — research tools and software, diagnostics, and CROs, other services and investors. Research topics come from each talk’s and session’s own title, or from an exhibitor’s own profile.

How current is it?

Pulled from the public schedule, the exhibitor floor plan and people’s own LinkedIn and Bluesky posts on September 29, 2026. SITC publishes its abstract titles and presenting authors’ institutions on October 2 and late-breaking abstract titles on October 29 — this guide adds them as they appear. Exhibit-hall hours are the poster hall’s published hours.

Browse SITC 2026 by

Organization type

Research topic

Exhibit hall

Exhibitors 132

Everyone

All organizations A–Z 242

Organizations with their own page

193 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction